145 Technologies found

UCLA researchers in the departments of Molecular, Cell & Developmental Biology and Biological Chemistry have elucidated a novel mechanism by which pyruvate oxidation can be inhibited in order to promote hair growth.

Through integrative analyses of the regeneration-associated gene expression profiling after peripheral nervous system (PNS) injury, combined with multi-level bioinformatics and experimental validation of network predictions, UCLA researchers in the Department of Neurology have identified a small molecule drug that significantly accelerates and improves dorsal root ganglia (DRG) neurite outgrowth in vitro and optic nerve outgrowth in vivo.

UCLA researchers in the Department of Psychiatry and Biobehavioral Sciences, Department of Radiation Oncology and Department of Pathology have identified sulfonamide-based small molecules that show anti-Zika activity at low nanomolar range.

Inventors at UC Irvine have engineered an orthogonal DNA replication system capable of rapid, accelerated continuous evolution. This system enables the directed evolution of specific biomolecules towards user-defined functions and is applicable to problems of protein, enzyme, and metabolic pathway engineering.

State of the art antimicrobial therapeutics, while effective and promising, remain only short-term solutions to the overall challenge of drug-resistant microbes. UCI researchers have developed a chitosan-based nanoantibiotic that is non-toxic and carries potential for broad spectrum use.

Researchers at the University of California, Davis, have identified a target for therapeutic intervention and agents that disrupt HIV latency in patients under suppressive HIV therapy. It amplifies the effects of other latency reversal agents and primes the cells harboring the virus for immune clearance and death.

UCLA researchers have developed ways to chemically modify NELL-1, an osteoinductive factor, that significantly prolong the in vivo circulation time of the protein and retain its osteoblastic activity without any appreciable cytotoxicity.

Researchers at the University of California, Davis have discovered a class of compounds that both bind to a unique newly-discovered binding site in respiratory complex III and act as inhibitors of electron transport for use as mitochondrial anti-cancer drugs.

Researchers at UCLA have found a small molecule that prevents the binding of DEPTOR to mTOR. The inhibition of interaction between DEPTOR and mTOR results in selective death of multiple myeloma cells, and can therefore be used as a targeted therapy for the disease.

Researchers from the Department of Neurology and the Department of Chemistry and Biochemistry at UCLA have developed a novel ERβ ligand prodrug that is structurally designed to more easily cross the blood-brain barrier for treatment of multiple sclerosis.

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.